| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-09-15 | Alnylam Pharmaceuticals (USA - MA) | Cancer - Oncology - Rare diseases - Infectious diseases | Nomination | |||
| 2014-09-15 | Gilead Sciences (USA - CA) Cadila Healthcare (India) Cipla (India) Hetero Labs (India) Mylan Laboratories (indian subsidiary of Mylan, USA - PA) Ranbaxy Laboratories (India) Sequent Scientific (India) Strides Arcolab (India) | sofosbuvir and edipasvir/sofosbuvir | hepatitis C | licensing |
Infectious diseases | Licensing agreement |
| 2014-09-15 | OncoCyte Corporation, BioTime, Inc.\'s Subsidiary (USA - CA) Abcodia (UK) | PanC-Dx™ | breast cancer | development |
Cancer - Oncology - Diagnostic | Development agreement |
| 2014-09-15 | Gilead (USA - CA) Zydus Cadila (India) | sofosbuvir (Sovaldi®) and ledipasvir/sofosbuvir (Harvoni®) | chronic hepatitis C genotype 1 infection | licensing |
Infectious diseases | Licensing agreement |
| 2014-09-15 | BioCardia (USA - CA) CellProThera (France) | protheracytes® CD34+ cells delivered by Helix™ transendocardial delivery system | acute myocardial infarction | clinical research |
Cardiovascular diseases | Clinical research agreement |
| 2014-09-12 | MRC (South Africa) GSK (UK) | non-communicable diseases such as cancer and diabetes | Cancer - Oncology - Metabolic diseases | Collaboration agreement | ||
| 2014-09-12 | RedXPharma (UK) | chief scientific officer, chief financial officer | nomination | Cancer - Oncology - Infectious diseases | Nomination | |
| 2014-09-11 | Merck KGaA, Merck Serono (Germany) BeiGene (China) | BGB-290 | development licensing commercialisation | Cancer - Oncology | Milestone | |
| 2014-09-11 | Cancer Research UK (UK) Cancer Research Technology (UK) Asterias Biotherapeutics (USA -CA) | AST-VAC2 | non-small cell lung cancer. | Cancer - Oncology - Regenerative Medicine | Clinical research agreement | |
| 2014-09-11 | Genomic Vision (France) | Technology - Services | Nomination | |||
| 2014-09-11 | Sophia Genetics (Switzerland) undisclosed leading Turkish laboratory (Turkey) | Data Driven Medicine platform | services |
Technology - Services | Services contract | |
| 2014-09-11 | Sophia Genetics (Switzerland) NHS (UK) | Data Driven Medicine platform | services |
Technology - Services | Services contract | |
| 2014-09-10 | Genmab (Denmark) Seattle Genetics (USA - WA) | auristatin-based antibody-drug conjugate (ADC) technology, HuMax®-AXL | solid tumors | Cancer - Oncology | R&D agreement | |
| 2014-09-10 | Novimmune (Switzerland) | Cancer - Oncology - Immunological diseases - Inflammatory diseases | Nomination | |||
| 2014-09-10 | Eisai (Japan) Kyorin Pharmaceutical (Japan) | new antibacterial agents | collaboration |
Infectious diseases | Collaboration agreement | |
| 2014-09-09 | Relypsa (USA - CA) Patheon (USA - NC) | patiromer | hyperkalemia | Cardiovascular diseases - Metabolic diseases | Production agreement | |
| 2014-09-09 | Probiogen (Germany) | construction of new premises |
Technology - Services | Construction of new premises | ||
| 2014-09-08 | Acucela (USA - WA) | Ophtalmological diseases | Nomination | |||
| 2014-09-08 | Emergent BioSolutions (USA - MD) National Institute of Allergy and Infectious Diseases (NIAID) (USA) | AV7909 - dry formulation of NuThrax™ (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) | post-exposure prophylaxis of anthrax infection | development services |
Infectious diseases | Development agreement |
| 2014-09-04 | Abcam (UK) Cell Marque (USA - CA) | in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb® primary antibody portfolio | Diagnostic | Commercialisation agreement |
